We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
1
Tango Therapeutics
TNGX
$4.31B
$10.5M 3.3%
502,012
+286,840
+133% +$3.99M
RVMD icon
2
Revolution Medicines
RVMD
$44B
$7.86M 2.47%
80,792
+14,992
+23% +$1.51M
TYRA icon
3
Tyra Biosciences
TYRA
$1.51B
$7.49M 2.35%
195,685
+116,125
+146% +$3.76M
LQDA icon
4
Liquidia Corp
LQDA
$7.05B
$7.09M 2.23%
187,876
+96,609
+106% +$3.58M
AGIO icon
5
Agios Pharmaceuticals
AGIO
$2.04B
$7.09M 2.23%
209,547
+177,809
+560% +$5.04M
IPSC icon
6
Century Therapeutics
IPSC
$355M
$6.66M 2.09%
+2,947,826
New +$6.2M
ELVN icon
7
Enliven Therapeutics
ELVN
$4.24B
$6.43M 2.02%
164,030
+64,077
+64% +$1.78M
PCVX icon
8
Vaxcyte
PCVX
$8.88B
$6.3M 1.98%
108,450
+83,085
+328% +$4.51M
COGT icon
9
Cogent Biosciences
COGT
$6.76B
$5.75M 1.81%
149,399
-64,700
-30% -$2.39M
CGON icon
10
CG Oncology
CGON
$6.82B
$5.13M 1.61%
75,758
-1,439,393
-95% -$81.6M
PHVS icon
11
Pharvaris
PHVS
$2.55B
$4.88M 1.53%
172,731
+117,389
+212% +$3.14M
ABVX
12
Abivax
ABVX
$10.9B
$4.79M 1.51%
43,052
+29,553
+219% +$3.5M
DNTH icon
13
Dianthus Therapeutics
DNTH
$6.29B
$4.55M 1.43%
54,258
+39,607
+270% +$2.29M
CYTK icon
14
Cytokinetics
CYTK
$10.5B
$4.04M 1.27%
61,269
+50,934
+493% +$3.24M
SLNO
15
DELISTED
Soleno Therapeutics
SLNO
$3.88M 1.22%
115,770
-14,309
-11% -$561K
ERAS icon
16
Erasca
ERAS
$6.5B
$3.6M 1.13%
+222,468
New +$2.63M
ROIV icon
17
Roivant Sciences
ROIV
$26.1B
$3.55M 1.12%
+128,168
New +$3.29M
AVTX icon
18
Avalo Therapeutics
AVTX
$1.05B
$3.19M 1%
213,819
+150,476
+238% +$2.35M
EPRX
19
Eupraxia Pharmaceuticals
EPRX
$423M
$3.14M 0.99%
+433,515
New +$3.49M
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.56B
$2.87M 0.9%
+86,283
New +$2.89M
TSHA icon
21
Taysha Gene Therapies
TSHA
$2.05B
$2.8M 0.88%
625,708
+458,485
+274% +$2.13M
ASND icon
22
Ascendis Pharma A/S
ASND
$16.8B
$2.79M 0.88%
12,179
+6,509
+115% +$1.46M
CMPX icon
23
Compass Therapeutics
CMPX
$427M
$2.73M 0.86%
516,972
-51,775
-9% -$299K
DMRA
24
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.91B
$2.62M 0.82%
+101,248
New +$2.6M
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
$2.59M 0.81%
128,487
+80,075
+165% +$1.29M
1
2 3 4 5

Similar funds

SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
FNWM
Financial Network Wealth Management Draper, Utah $316M AUM
MJFG
Mars Jewett Financial Group Bellevue, Washington $316M AUM
KC
KHIS Custodian Dallas, Texas $316M AUM
EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
WA
Waterford Advisors Orchard Park, New York $315M AUM 15.21% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.